neurogene.com (NGNE): Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
This EV/EBITDA chart on the GURU.Markets platform is fixed at 0.00. The Neurogene Inc. (NGNE) business relies on the creation of gene therapies that require highly complex temperature-controlled transportation and reliable supply chains. Technological development is driven through alliances with academic institutions to assist critically ill children. Meanwhile, robust patent protection and stringent regulatory requirements create significant barriers to entry for new players.
NGNE (neurogene.com): analytical breakdowns and indicator data
- stock price and consensus target price:
- stock exchange capitalization data:
- book value of equity indicators:
- debt and solvency information:
- business earnings and investment ratios data:
NGNE - Net Financial Result|Expected Profit Neurogene Inc.|NGNE - Price to Earnings Multiple|Forward P/E Multiple Neurogene Inc.|NGNE - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio Neurogene Therapeutics|NGNE - Operating income before deduction of amortization|Earnings per share for the last twelve months Neurogene|NGNE - Earnings per share for the last 12 months|Quarterly EPS earnings growth neurogene.com|NGNE - Net earnings per share change in current year|Net earnings per share growth forecast for next year Neurogene Inc.
Fundamental company valuation:Neurogene Corp NGNE
Neurogene Inc. (NGNE) is facing supply chain disruptions during international gene therapy trials due to geopolitical fragmentation. Fluctuations in the EV/EBITDA multiple reflect the impact of these external risks on the business's market value relative to its operating profit. This metric compares the total value of the company, including debt and taxes, with its ability to generate cash flow. A decline in this metric signals that the asset is undervalued, provided the operating margin remains stable.
Competitor analysis
Biogen Corp - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Neurocrine Corp NBIX|RGC - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation AXSM (axsome.com)|ACADIA Pharmaceuticals Inc. (ACAD) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Xenon Pharmaceuticals Inc. (XENE)|VKTX (Viking Pharma) - EV/EBITDA Multiple|SUPN - Enterprise Value to EBITDA Multiple|EV/EBITDA Multiple CPRX|DNLI - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harmony Biosciences Holdings, Inc. HRMY|BHVN: Enterprise Value to Operating Income Before Depreciation|Amylyx - EV/EBITDA Multiple|Company Value to EBITDA Trevi Corp|PRAX (Praxis Precision Medicines) - Enterprise Value to EBITDA Ratio|anavex.com - Business Value to Operating Income Before Depreciation|CBLL (CeriBell) - EV/EBITDA Multiple|Prothena Corporation PLC (PRTA) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alector, Inc. (ALEC)|Annexon Biosciences Inc. - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple OMER (Omeros)|ACIU - Enterprise Value to EBITDA Ratio|VYGR: Enterprise Value to EBITDA Ratio|Total Company Value to Operating Income Before Depreciation Ratio Neumora NMRA|Scilex Holding Co. (SCLX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation TVGN|ACOG (Alpha Cognition Inc) - EV/EBITDA Multiple|CGTX - Enterprise Value to EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Inhibikase Therapeutics, Inc. (IKT)|Cassava Sciences Inc - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple ASRT (Assertio)|Coya Therapeutics Inc (COYA) - Company Value to EBITDA|VTGN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|OVID (Ovid Therapeutics Inc.) - Enterprise Value to Operating Income Before Depreciation|ABOS: EV/EBITDA Multiple|Company Value to EBITDA CervoMed, Inc. (CRVO)|Enterprise Value to EBITDA Ratio ATHE|EV/EBITDA Multiple Clene Nanomedicine|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PepGen Inc. (PEPG)|JUNS (jupiterneurosciences.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Relmada Therapeutics, Inc. RLMD|Annovis Bio Inc (ANVS) - Company Value to EBITDA|GRCE - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|AIFF (Firefly Neuro) - Enterprise Value to Operating Income Before Depreciation|KLTO: EV/EBITDA Multiple|Company Value to EBITDA NeuroSense Therapeutics Ltd. (NRSN)|Enterprise Value to EBITDA Ratio RVPH|EV/EBITDA Multiple MetaVia, Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeurAxis, Inc (NRXS)|HSDT (heliusmedical.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Passage Bio PASG|Neuphoria Therapeutics, Inc. (NEUP) - Company Value to EBITDA|Minerva Neurosciences, Inc. - EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Athira Pharma Inc (ATHA)|ADXN: EV/EBITDA Multiple|Company Value to EBITDA Alzamend Neuro (ALZN)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cyclerion Therapeutics Inc.|Enterprise Value to Operating Income Before Depreciation PTIX (Protagenic)|EV/EBITDA Multiple KTTA|CRGT - Company Value to EBITDA|Avenue Therapeutics, Inc - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation BCLI|Cara Therapeutics, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio chromocell.com CHRO|eliemtx.com (ELYM) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation ITCI|LBPH (Longboard Pharma) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Marinus Pharma (MRNS)|Enterprise Value to EBITDA Ratio NKGN (NKGen Biotech, Inc.)|Total Company Value to Operating Income Before Depreciation Ratio neurobopharma.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sage Therapeutics SAGE|SNPX: Enterprise Value to Operating Income Before Depreciation|Trevena, Inc - EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Vigil Neuroscience (VIGL)|Anew Medical, Inc. (WENA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation CERE
